Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2000

View Archived Issues

Phase II results reported for tenofovir DF

Pivotal trial of Fabrazyme meets primary endpoint

Medarex and Centocor sign antibody development agreement

Transgenic antibody production agreement signed by Genzyme Transgenics and Abgenix

LigoCyte awarded Phase II SBIR grant for nanoparticle technology

Connetics continues to expand relaxin indications

Corixa expands technology through five new collaborative agreements

Q1 2000 marked by significant achievements at Elan

AxyS makes considerable progress in drug discovery and development programs during Q1 2000

Anti-human CD40 antibodies designed by BMS for use in immune disorders and inflammation

Final results of phase I/IIa trial evaluating CAT-152 in trabeculectomy patients announced at ARVO

Isis prepares antisense modulators of FAN expression

Schering prepares new fluorescent contrast agents for imaging tumors and blood vessels

News from ARVO: ISV-205 reduces corticosteroid-induced IOP elevations

Novel antifungal agent derived from BPI under study at Xoma

Tau protein kinase 1 inhibitors in development at Mitsubishi-Tokyo Pharmaceuticals

Oxazolidines and thiazolidines claimed by Roche Diagnostics for bone disorders

Preparation and biological evaluation of Cubist's new tRNA synthetase inhibitors described

New heterocyclic compounds from Procter & Gamble particularly useful for alopecia

Profile of KUL-7211, a new beta-adrenoceptor agonist with selectivity for ureteral smooth muscle

Actin polymerization inducer jasplakinolide improves outflow facility in primate model

Early clinical trial results in BPH suggest promise of new highly selective alpha1A blocker

A-204176 may increase IUP without cardiovascular side effects according to preclinical data

Clinical development of Neotrofin for AD reviewed at recent symposium

Celecoxib examined for effects on progression of AD in elderly in a 52-week study

Novel antiinflammatory drug tested in Sweden for efficacy in Alzheimer's disease

Nucleoside analogues with activity against herpesviruses developed by Japanese research team

No consistent cognitive or motor effects detected for SIB-1508Y in safety study in early PD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...